Compare ASMB & BGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASMB | BGB |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.9M | 506.7M |
| IPO Year | 2010 | N/A |
| Metric | ASMB | BGB |
|---|---|---|
| Price | $25.50 | $11.28 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $44.20 | N/A |
| AVG Volume (30 Days) | ★ 184.0K | 116.8K |
| Earning Date | 05-06-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.75% |
| EPS Growth | ★ 91.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $638.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.81 | $10.85 |
| 52 Week High | $39.71 | $12.65 |
| Indicator | ASMB | BGB |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 45.75 |
| Support Level | $22.49 | $11.16 |
| Resistance Level | $30.80 | $11.53 |
| Average True Range (ATR) | 1.52 | 0.06 |
| MACD | 0.44 | 0.00 |
| Stochastic Oscillator | 59.56 | 42.31 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
Blackstone Strategic Credit Fund is a diversified, closed-end management investment company. Its primary investment objective is to seek high current income. The secondary objective of the fund is to seek the preservation of capital. Under normal market conditions, the Fund invests at least 80% of its Managed Assets in senior, secured floating-rate loans. The fund also invest in second-lien loans and high yield bonds and employs financial leverage, which may increase risk to the Fund. The Fund has a limited term and absent shareholder approval to extend the life of the Fund.